Fairvalue-Calculator Fairvalue-Calculator
EN DE

CytoDyn Inc (CYDY) Fair Value & Analysis

Healthcare · US · Market cap $370M

Price$0.2639
Fair Value$0.0900
Upside-65.9%
Quality95/100
Evidence: Medium Range $0.0600 – $0.1100

Fair value as of: Jun 24, 2026

Analysis

CytoDyn Inc (CYDY) currently trades at $0.2639, while our model-based Fair Value estimate is $0.0900 — implying the stock looks roughly 65.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is CytoDyn Inc (CYDY) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.0900 versus a price of $0.2639 — about −66% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CYDY?
Our 21-model fair value for CytoDyn Inc is $0.0900 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.2639.
What is the quality score of CYDY?
CytoDyn Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.